Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
Researchers hoped they had finally found a way to get gene therapies past the blood-brain barrier. Then the first patient ...
A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.
A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...
An experimental gene therapy treatment created at UCLA gave a "bubble girl" born with a rare genetic disorder a new life.
The donation from Don and Anne Edwards aims to speed research, treatment and diagnosis for children with rare and genetic ...
Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...
For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback